169 related articles for article (PubMed ID: 19838163)
1. Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins.
Zhuang L; Scolyer RA; Murali R; McCarthy SW; Zhang XD; Thompson JF; Hersey P
Mod Pathol; 2010 Jan; 23(1):45-53. PubMed ID: 19838163
[TBL] [Abstract][Full Text] [Related]
2. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Hersey P
Mod Pathol; 2007 Apr; 20(4):416-26. PubMed ID: 17384650
[TBL] [Abstract][Full Text] [Related]
3. Expression of apoptosis regulators in cutaneous malignant melanoma.
Tang L; Tron VA; Reed JC; Mah KJ; Krajewska M; Li G; Zhou X; Ho VC; Trotter MJ
Clin Cancer Res; 1998 Aug; 4(8):1865-71. PubMed ID: 9717813
[TBL] [Abstract][Full Text] [Related]
4. Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma.
Zhuang L; Scolyer RA; Lee CS; McCarthy SW; Cooper WA; Zhang XD; Thompson JF; Hersey P
Histopathology; 2009 Mar; 54(4):462-70. PubMed ID: 19309398
[TBL] [Abstract][Full Text] [Related]
5. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma.
Leiter U; Schmid RM; Kaskel P; Peter RU; Krähn G
Arch Dermatol Res; 2000 May; 292(5):225-32. PubMed ID: 10867810
[TBL] [Abstract][Full Text] [Related]
6. Mcl-1 is required for melanoma cell resistance to anoikis.
Boisvert-Adamo K; Longmate W; Abel EV; Aplin AE
Mol Cancer Res; 2009 Apr; 7(4):549-56. PubMed ID: 19372583
[TBL] [Abstract][Full Text] [Related]
7. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
8. Myeloid leukemia-1 expression in benign and malignant melanocytic lesions.
Wong RP; Khosravi S; Martinka M; Li G
Oncol Rep; 2008 Apr; 19(4):933-7. PubMed ID: 18357378
[TBL] [Abstract][Full Text] [Related]
9. Bcl-xL and bcl-2 proteins in melanoma progression and UVB-induced apoptosis.
Zhang H; Rosdahl I
Int J Oncol; 2006 Mar; 28(3):661-6. PubMed ID: 16465371
[TBL] [Abstract][Full Text] [Related]
10. IMP-3 is a novel progression marker in malignant melanoma.
Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H
Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432
[TBL] [Abstract][Full Text] [Related]
11. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.
Peddaboina C; Jupiter D; Fletcher S; Yap JL; Rai A; Tobin RP; Jiang W; Rascoe P; Rogers MK; Smythe WR; Cao X
BMC Cancer; 2012 Nov; 12():541. PubMed ID: 23171055
[TBL] [Abstract][Full Text] [Related]
12. Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma.
Papalas JA; Vollmer RT; Gonzalez-Gronow M; Pizzo SV; Burchette J; Youens KE; Johnson KB; Selim MA
Mod Pathol; 2010 Jan; 23(1):134-43. PubMed ID: 19838160
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
14. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
[TBL] [Abstract][Full Text] [Related]
15. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
16. Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression.
Xu XZ; Garcia MV; Li TY; Khor LY; Gajapathy RS; Spittle C; Weed S; Lessin SR; Wu H
Mod Pathol; 2010 Feb; 23(2):187-96. PubMed ID: 19898426
[TBL] [Abstract][Full Text] [Related]
17. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
18. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
19. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines.
Selzer E; Schlagbauer-Wadl H; Okamoto I; Pehamberger H; Pötter R; Jansen B
Melanoma Res; 1998 Jun; 8(3):197-203. PubMed ID: 9664140
[TBL] [Abstract][Full Text] [Related]
20. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
